Join the Oncology
Community
Follow Us:  

Patient & Survivor Care

Jaw Complications Persist With Head & Neck Cancer Treatment

By: MIRIAM E. TUCKER,  Oncology Report Digital Network

PHOENIX – An analysis of Medicare data for more than 1,800 head and neck cancer patients suggests that jaw complications following radiation treatment may be more common than recognized.

Moreover, intensity-modulated radiation therapy (IMRT) was not associated with significantly lower rates of jaw complications, compared with older radiation techniques, although there was a slight trend in that direction and the interval to developing jaw complications was longer following IMRT, reported Dr. Beth M. Beadle at a head and neck cancer symposium sponsored by the American Society for Radiation Oncology.

Photo: courtesy Theresa Hofstede, D.D.S.

Since 1997, 25 retrospective and prospective studies involving 9,632 patients overall have reported an overall average osteoradionecrosis rate of 3.0%, Dr. Beth M. Beadle said.

 

In the literature, osteoradionecrosis (ORN), the most severe jaw manifestation resulting from head/neck radiation, was reported on average in 11.8% of patients in 10 studies (total, 3,312 irradiated patients) from the 1930s through the 1960s, said Dr. Beadle, a radiation oncologist at the University of Texas M.D. Anderson Cancer Center, Houston.

With improved technologies, the rate dropped to 5.4%, as documented in 21 studies involving a total of 11,077 patients conducted from the 1970s through the early 1990s. Since 1997, 25 retrospective and prospective studies involving 9,632 patients overall have reported an overall average ORN rate of 3.0%, she said.

For the current study, data were taken from the SEER (Surveillance, Epidemiology, and End Results) database for Medicare beneficiaries. Patients who were diagnosed with oral cancers in 1999-2007 were identified using SEER, ICD-9, and CPT codes. Primary tumor sites included those of the lip, tongue, floor of mouth, gum, tonsil, oropharynx, and other oral cavity and pharynx.

Of 1,848 patients overall, 16.1% (297) had at least one osteoradionecrosis code within 90 days of radiation therapy completion. Of those, 256 patients had ICD-9 diagnostic codes that included those for osteonecrosis of jaw (733.45), osteomyelitis of jaw (526.4), and other diseases of the jaws, including inflammatory conditions, alveolitis, and periradicular pathology (all 526.x).

Some 41 patients (3.8% of the total) had CPT procedure codes, including drainage of abscess (41800), alveolectomy (41830), operations on facial bones or joints with concurrent ORN diagnosis (76.3), or hyperbaric oxygen therapy (99183), and 30 patients (1.6% of the total) had both a diagnostic and a procedural ORN code, Dr. Beadle said.


Dr. Beth M. Beadle

 

The percentage of patients who required intervention for ORN (3.8%) is more consistent with the overall ORN rates from the literature, suggesting that most previous studies have captured only the more severe osteoradionecrosis, which is usually defined as that requiring a procedure, she explained.

In univariate analysis, female sex, not receiving chemotherapy, and a lower number of comorbidities on the Charlson Comorbidity Index were the only factors significantly associated with all jaw complications.

Receipt of IMRT was not a significant predictor, although there was a trend. Patients who received IMRT differed significantly from non-IMRT patients in several ways, however, including their younger age and their greater likelihood to be male, to have advanced-stage disease, to have received definitive vs. adjuvant treatment, to have received chemotherapy, and to have fewer comorbidities.

02/13/12  

FROM A HEAD AND NECK CANCER SYMPOSIUM SPONSORED BY THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

Bookmark and Share


Submitting your vote...
Not rated yet. Be the first who rates this item!
Click the rating bar to rate this item.

Vitals

Major Finding: Of a total 1,848 patients with oral cancers, 16% (297) had at least one osteoradionecrosis code within 90 days of radiation therapy completion.

Data source: Data were taken from the SEER database for Medicare beneficiaries.

Disclosures: Dr. Beadle reported having no financial disclosures.

Current Issue


The Oncology Report Comprehensive reports and expert commentary on the latest advances in cancer treatment from the world's major oncology meetings.

Past issues, click here »


calendar
Jun 1 - 5
Chicago, IL
American Society of Clinical Oncology (ASCO): Annual Meeting
Jun 14 - 17
Amsterdam,
European Hematology Association (EHA): Annual Congress
Jun 18 - 21
Lake Tahoe, NV
American Association for Cancer Research (AACR): Pancreatic Cancer: Progress and Challenges
Jun 20 - 22
Milan,
European Institute of Oncology (IEO): 14th Milan Breast Cancer Conference
Jun 25 - 26
London,
Teenage Cancer Trust (TCT): International Conference
Jun 27 - 30
Barcelona,
European Society for Medical Oncology (ESMO) Conference: World Congress on Gastrointestinal Cancer
Jun 27 - 30
Boston, MA
American Association for Cancer Research (AACR): Chemical Systems Biology
Jun 28 - 30
New York, NY
Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium
Jun 28 - 29
Paris,
WIN 2012 Symposium
Jul 7 - 10
Barcelona,
22nd Biennial Congress of the European Association for Cancer Research
More Calendar »